当前位置: 首页 > 期刊 > 《健康周刊》 > 20188
编号:13598315
抗凝类药物研究进展(2)
http://www.100md.com 2018年2月26日 《健康周刊》 20188
     參考文献

    [1]徐丹洋,马长振,陈佩东,等. 茅根炭止血机理的实验研究[J]. 中成药,2010,12(32):2114 -2117.

    [2]Jung WK, Kim SK. Isolation and characterization of an anticoagulant oligoPePtide from blue mussel, Mytilus edulis[J]. Food Chemistry, 2009, 117(4): 687-692.

    [3]Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiPlatelet and anticoagulant treatments[J]. Lancet, 2015,386(9990): 281-291.

    [4]Zikria JC, Ansell J. Oral anticoagulation with factor Xa andthrombin inhibitors: on the threshold of change[J]. Current OPinion in Hematology, 2009,16(5): 347-356.

    [5]Koh CY, Kini RM. Molecular diversity of anticoagulants from haematoPhagous animals[J]. Thrombosis & Haemostasis, 2009, 102(3): 437-453.

    [6] Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interPretation of coagulation assays and reversal of anticoagulant activity[J]. Thrombosis &Haemostasis, 2010, 103(6): 1116-1127.

    [7]Jo HY, Jung WK, Kim SK. Purification and characterization of a novel anticoagulant PePtide from marine echiuroid worm, Urechis unicinctus[J]. Journal of Biochemistry, 2008, 43(2):179-184.

    [8]Jung WK, Je JY, Kim HJ, et al. A novel anticoagulant Protein from ScaPharca broughtonii. Journal of Biochemistry and Molecular Biology, 2001, 35 (2):199-205., 百拇医药(黄爱容)
上一页1 2